Precocious Puberty Clinical Trial
Official title:
Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS)
Verified date | May 18, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test the safety and effectiveness of letrozole in treating precocious (early)
puberty in girls with McCune-Albright syndrome (MAS). The physical changes of puberty, such
as breast enlargement, menstruation and growth spurt, as well as the emotional changes of
this developmental stage, usually begin in girls between the ages of 8 and 14. Girls with
MAS, however, often begin puberty before age 7. In MAS, large ovarian cysts produce high
levels of estrogens (female hormones) that cause the changes of puberty. Children with MAS
also have polyostotic fibrous dysplasia (PFD), a disease of bones that, depending on what
parts of the skeleton are affected, can lead to broken bones or disfigurement of the head,
face, arms and legs, or can cause pressure on nerves and blood vessels. Many children with
MAS have cafe-au-lait spots (increased pigmentation) on areas of their skin as well.
Letrozole is an estrogen-lowering drug that has been approved for treating women with breast
and other cancers. Although the drug has not been tested or approved for use in children,
some pediatric specialists have given it to girls with precocious puberty and MAS and found
that it improves their condition without harmful side effects. This study will examine
whether letrozole can lower estrogen in girls with MAS and arrest puberty. It will also study
the drug's effects on substances involved in bone growth, including calcium, phosphate and
amino acids.
Girls 1 to 8 years old with MAS may be eligible for this study. Patients who were enrolled in
NIH protocol 98-D-0145 (Screening and Natural History of Patients with Polyostotic Fibrous
Dysplasia and the McCune-Albright syndrome) are also eligible. Participants will be admitted
to the hospital for 2 to 3 days every 3 months for 15 months, for a total of 6 visits. They
will undergo a complete history and physical examination and routine blood and urine tests
every visit, as well as evaluations of their general health, growth and bone development,
endocrine system (hormone-secreting glands) status and PFD status. A hand X-ray will be taken
at the first visit and every 6 months to measure bone age advance. The children will begin
taking letrozole at the second visit and continue the drug for 6 months. They will be
evaluated after 3 months and 6 months on the drug (visits 3 and 4), and again after 3 months
and 6 months after stopping treatment (visits 5 and 6).
Parents of children who weigh more than 18 kilograms (about 40 pounds) may be asked if extra
blood may be drawn after 3 months (visit 3) and 6 months (visit 4) of treatment to measure
letrozole levels. The blood will be drawn before the morning dose and at 0.5, 1, 1.5, 2, 3,
4, 6, 8, and 24 hours after the dose through an indwelling needle placed in the vein for 8 to
24 hours.
Parents will keep a record of all episodes of menstrual bleeding and any other symptoms or
complaints. Children who respond well to therapy (decreased menses, slowed breast
development, slowed growth and bone age advance) will be offered another 12 months of
letrozole treatment.
Status | Completed |
Enrollment | 25 |
Est. completion date | May 18, 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 1 Year to 8 Years |
Eligibility |
- INCLUSION CRITERIA Patients will be girls age 1-8 years with precocious puberty (menses, and/or breast development, and/or BA greater than plus 2SD [for chronologic age] and/or linear growth rate greater than plus 2SD) and polyostotic fibrous dysplasia due to MAS. All ethnic groups will be included. EXCLUSION CRITERIA Boys with MAS will be excluded. Patients with clinically significant hepatic and/or renal impairment will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01944488 -
LH Response to GnRH Test in Prepubescent Girls Under 6 Years
|
N/A | |
Not yet recruiting |
NCT01944475 -
Follow-up of Girls With Premature Thelarche and Precocious Puberty
|
N/A | |
Completed |
NCT00564850 -
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
|
Phase 3 | |
Completed |
NCT00001181 -
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
|
Phase 2 | |
Recruiting |
NCT04113070 -
Overweight and Obesity and Puberty Development Cohort Study
|
||
Recruiting |
NCT01601171 -
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
|
||
Completed |
NCT00734279 -
Follicle-Stimulating Hormone (FSH) and the Onset of Puberty
|
Early Phase 1 | |
Recruiting |
NCT05338411 -
Effect of Exogenous Growth Hormone on Ocular Findings
|
||
Recruiting |
NCT06280807 -
Observation of Environment and Reproductive-Endocrine Effects
|
||
Completed |
NCT00004344 -
Purification of Testis-Stimulating Factor in Precocious Puberty
|
N/A | |
Completed |
NCT00001202 -
Treatment of Boys With Precocious Puberty
|
Phase 2 | |
Completed |
NCT04665713 -
Effect of Prevalence of BMI on Efficacy of Herbal Medicines in Girls' Sexual Precocity
|
||
Completed |
NCT02199587 -
The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test
|
N/A | |
Terminated |
NCT04502836 -
Evaluation of the Correlation Between Psychological Intervention, Including Providing Knowledge and Tools for Problems Solving, and the Anxiety Level of Female Patients Arriving to ACTH LRH Test - Pilot Study
|
N/A | |
Completed |
NCT02650141 -
Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty
|
N/A | |
Completed |
NCT00909844 -
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
|
Phase 3 | |
Completed |
NCT00004335 -
Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle
|
N/A |